Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

  • Showing results for l. pienta. Your search for L. Pienti retrieved no results.
1.

Tenascin-C and Integrin α9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment.

San Martin R, Pathak R, Jain A, Jung SY, Hilsenbeck SG, Piña-Barba MC, Sikora AG, Pienta KJ, Rowley DR.

Cancer Res. 2017 Nov 1;77(21):5977-5988. doi: 10.1158/0008-5472.CAN-17-0064. Epub 2017 Sep 15.

2.

Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine.

Glinskii OV, Sud S, Mossine VV, Mawhinney TP, Anthony DC, Glinsky GV, Pienta KJ, Glinsky VV.

Neoplasia. 2012 Jan;14(1):65-73.

3.

CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization.

Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ.

J Biol Chem. 2009 Dec 4;284(49):34342-54. doi: 10.1074/jbc.M109.042671. Epub 2009 Oct 15.

4.

Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G.

Lancet Oncol. 2009 Mar;10(3):233-9. doi: 10.1016/S1470-2045(08)70340-1. Epub 2009 Feb 11.

6.

Galectin-3 as a potential therapeutic target in tumors arising from malignant endothelia.

Johnson KD, Glinskii OV, Mossine VV, Turk JR, Mawhinney TP, Anthony DC, Henry CJ, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV.

Neoplasia. 2007 Aug;9(8):662-70.

7.

GREB1 is a novel androgen-regulated gene required for prostate cancer growth.

Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM, Pienta KJ, Lippman ME.

Prostate. 2006 Jun 1;66(8):886-94.

PMID:
16496412
8.

Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs.

Glinskii OV, Huxley VH, Glinsky GV, Pienta KJ, Raz A, Glinsky VV.

Neoplasia. 2005 May;7(5):522-7.

9.

Differential carbohydrate expression in tumorigenic vs nontumorigenic prostate cell-lines.

Pacis R, Pilat M, Yamazaki K, Pienta K.

Int J Oncol. 1995 Dec;7(6):1349-54.

PMID:
21552971
10.

Inhibition of prostate cancer growth by estramustine and colchicine.

Fakih M, Yagoda A, Replogle T, Lehr JE, Pienta KJ.

Prostate. 1995 Jun;26(6):310-5.

PMID:
7784270
11.

Inhibition of prostate cancer growth by vinblastine and tamoxifen.

Pienta KJ, Replogle T, Lehr JE.

Prostate. 1995 May;26(5):270-4.

PMID:
7753712
12.

4-Hydroxyphenylretinamide in the chemoprevention of cancer.

Naik HR, Kalemkerian G, Pienta KJ.

Adv Pharmacol. 1995;33:315-47. Review.

PMID:
7495674
13.
14.

Alterations in cellular gene expression without changes in nuclear matrix protein content.

Macoska J, Hoover CN, Pienta KJ.

J Cell Biochem. 1994 Dec;56(4):502-9.

PMID:
7890808
15.

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

Pienta KJ, Redman B, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE.

J Clin Oncol. 1994 Oct;12(10):2005-12.

PMID:
7523606
16.

The epidemiology of prostate cancer: clues for chemoprevention.

Pienta KJ.

In Vivo. 1994 May-Jun;8(3):419-22. Review.

PMID:
7803727
17.

An unstable nuclear matrix may contribute to genetic instability.

Pienta KJ, Ward WS.

Med Hypotheses. 1994 Jan;42(1):45-52.

PMID:
8196560
18.

Tumor-associated angiogenesis in prostate cancer.

Fregene TA, Khanuja PS, Noto AC, Gehani SK, Van Egmont EM, Luz DA, Pienta KJ.

Anticancer Res. 1993 Nov-Dec;13(6B):2377-81.

PMID:
7510938
19.

Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo.

Nguyen NM, Lehr JE, Pienta KJ.

Anticancer Res. 1993 Nov-Dec;13(6A):2143-7.

PMID:
7507655
20.

The effect of maltose tetrapalmitate (MTP) on prostate cancer growth in vivo and in vitro.

Nguyen NM, Lehr JE, Shelley CI, Andersen JC, Pienta KJ.

Anticancer Res. 1993 Nov-Dec;13(6A):2053-8.

PMID:
7507653

Supplemental Content

Loading ...
Support Center